5CV — CureVac NV Income Statement
0.000.00%
Last trade - 00:00- €639.96m
- €193.56m
- €535.18m
- 66
- 92
- 46
- 81
Annual income statement for CureVac NV, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 48.9 | 103 | 67.4 | 53.8 | 535 |
| Cost of Revenue | |||||
| Gross Profit | 34.7 | -135 | -91.6 | -62.5 | 429 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 159 | 515 | 317 | 328 | 357 |
| Operating Profit | -110 | -412 | -249 | -274 | 178 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -130 | -412 | -249 | -260 | 191 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -129 | -412 | -249 | -260 | 162 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -129 | -412 | -249 | -260 | 162 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -129 | -412 | -249 | -260 | 162 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.716 | -2.35 | -1.17 | -1.03 | 0.809 |